The Effect of Multi-strain Probiotic Formulation on Gastrointestinal Symptoms, Quality of Life and Mental Health in Patients With Functional Dyspepsia: a Randomized Dietary Trial

The goal of this clinical trial is to learn whether a multi-strain probiotic can reduce digestive symptoms and improve quality of life in adults with functional dyspepsia. The main questions it aims to answer are:
* Does the probiotic reduce symptoms such as fullness after meals, bloating, stomach discomfort, and early satiation?
* Does the probiotic improve emotional well-being, including stress, anxiety, and mood? Researchers will compare the probiotic to a placebo (a look-alike capsule with no active ingredients) to see if the probiotic truly helps adults with functional dyspepsia.
Participants will:
* Take one capsule of the probiotic or placebo once daily before meals for 60 days
* Complete questionnaires about their digestive symptoms at the start, 1 month, and 2 months
* Complete surveys on stress, anxiety, depression, and quality of life at the start and 2 months
* Attend scheduled study visits for checkups and assessments

Start Date05 Jan 2026

Sponsor / Collaborator-

ChiCTR2500115398

/ Not yet recruitingPhase 1IIT

Research on the Influence and Mechanism of Probiotics on Peristomal Dermatitis in Patients

Start Date01 Jan 2026

Sponsor / Collaborator-

IRCT20250217064748N1

/ SuspendedPhase 3IIT

Studying the effect of probiotic Lactobacillus reuteri on blood sugar control in children with type 1 diabetes: A randomized, double-blind clinical trial study

Start Date24 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Lactobacillus reuteri

100 Translational Medicine associated with Lactobacillus reuteri

100 Patents (Medical) associated with Lactobacillus reuteri

945

Literatures (Medical) associated with Lactobacillus reuteri

01 Apr 2026·MICROBIAL PATHOGENESIS

Evaluating probiotic monotherapy in Helicobacter pylori infection: A meta-analysis of randomized controlled trials with trial sequential analysis

Article

Author: Pathak, Sushil Kumar ; Dash, Debabrata ; Panda, Aditya K ; Mishra, Vivek

BACKGROUND:

This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of probiotics in reducing H. pylori colonization in non-antibiotic interventions.

METHODS:

Systematic searches were conducted in PubMed, Scopus, Cochrane Library databases and Google Scholar. Data analysis was performed using CMA (V4) and Trial Sequential Analysis (TSA), with evidence certainty evaluated via GRADE.

RESULTS:

Twenty-eight studies met the inclusion criteria. Compared with placebo, probiotic monotherapy significantly reduced H. pylori colonization (RR = 1.712, 95 % CI: 1.240 to 2.364, I² = 37.80, p = 0.001), but total eradication was 16.8 %. Among the probiotic strains, Lactobacillus reuteri showed higher efficacy (event rate = 0.377, 95 % CI: 0.123 to 0.722, I² = 86.00). 4 weeks supplementation period yielded a stronger effect (event rate = 0.315, 95 % CI: 0.137 to 0.570, I² = 78.18). Changes in ¹³C-UBT values, indicating bacterial load reduction, were significant (SMD = -0.617, p < 0.001, 95 % CI: -0.921 to -0.312, I² = 86.50), while gastrointestinal symptom relief scores showed moderate improvement (SMD = -0.253, p = 0.012, 95 % CI: -0.451 to -0.055, I² = 2.46). TSA validated that sufficient studies supported these findings, with evidence graded of moderate certainty.

CONCLUSION:

While probiotic monotherapy, particularly L. reuteri appears to reduce H. pylori colonization and improve gastrointestinal symptoms, their effectiveness as a standalone therapy remains limited owing to low eradication rates and variability in study quality. Further well-designed trials are required to establish their optimal role, particularly as supportive or adjunctive interventions.

01 Apr 2026·POULTRY SCIENCE

Free amino-acid and imidazole-ring dipeptide profiles of chicken-liver-hydrolysate supplement and its modulatory effects on lipid metabolism, oxidative status, and inflammation in livers, as well as gut microbiota in a high-fat diet

Article

Author: Sutopo, Christoper Caesar Yudho ; Lin, Yi-Ling ; Wang, Sheng-Yao ; Kao, Yi-Feng ; Chen, Jr-Wei ; Chen, Yi-Chen

Chicken livers can be sustainably developed into nutraceuticals through the circular-agriculture innovation chain. A supplement (GBHP01) formulated from chicken-liver hydrolysates contains free-type hypolipidemic amino acids (threonine, valine, leucine, isoleucine, and taurine) and the imidazole-ring dipeptide (anserine). In this study, mice were assigned to four groups: (1) Control: control diet (AIN-93M formula; fat providing 9.4% of total calories), (2) HFD: high-fat diet (fat providing 46.5% of total calories), (3) GBHP01.L: HFD supplemented with GBHP01 at 133.61 mg/Kg BW/day, and (4) GBHP01.H: HFD supplemented with GBHP01 at 267.22 mg/Kg BW/day. GBHP01 was administered by oral gavage. In 20-week HFD feeding, GBHP01 supplementation significantly reduced serum lipids, ALT, AST, and hepatic tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) concentrations, while enhancing reduced GSH, TEAC, catalase, and GSH-Px levels (p<0.05). Histological analysis revealed decreased hepatic lipid accumulation, associated with decreased diacylglycerol O-acyltransferase 2 (DGAT2) and increased acyl-CoA dehydrogenase medium chain (ACADM) expression. GBHP01 also promoted fecal bile acid and triglyceride excretion, indicating reduced fat absorption. Fecal microbiota profiling showed that HFD disrupted microbial diversity, increasing detrimental genera (Desulfovibrio, Bilophila, and Lachnoclostridium) while decreasing beneficial taxa (Lactobacillus and Akkermansia). GBHP01 may contribute to shifts in gut microbial composition by elevating probiotic species (L. reuteri and L. murinus) and reducing inflammatory taxa (Bilophila and Mucispirillum), suggesting its potential as a dietary intervention against HFD-induced metabolic disorders.

01 Feb 2026·JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE

The ethanol extract derived from mung bean reduced immune suppression, intestinal injury, and disruptions in gut microbiota caused by cyclophosphamide in mice

Article

Author: Bai, Jing ; Guo, Jinlin ; Liao, Zhengyue ; Cao, Xiaonian ; Liu, Yixin ; Liu, Sijing ; Niu, Shuqi ; Huang, Zhangjun ; Shen, Caihong

Abstract:

BACKGROUND:

Cyclophosphamide ( CTX ), a widely utilized alkylating agent in cancer chemotherapy, is known to exert potent antitumor effects. However, it often induces severe adverse effects, including immunosuppression and intestinal mucosal injury. Mung bean ( Vigna radiata L.), a legume rich in flavonoid compounds, has potential immunomodulatory properties. This study sought to explore the protective roles of mung bean ethanolic extract ( MBE ) against CTX ‐induced immunosuppression and intestinal damage, emphasizing the alteration of gut microbiota and underlying molecular mechanisms. In this research, a murine model with immunosuppression induced by CTX was utilized. Immune function was evaluated through the examination of spleen and thymus indices, lymphocyte proliferation and cytokine levels. Additionally, flow cytometry was employed to analyze CD4+ and CD8+ T cell subsets, while splenic histopathology was examined using hematoxylin and eosin (H&E) staining. The integrity of the intestinal barrier was investigated through periodic acid–Schiff and H&E staining, complemented by reverse transcription–quantitative polymerase chain reaction and western blotting to quantify the expression levels of colonic tight junction proteins. Gut microbiota composition was analyzed using 16S rRNA sequencing. Furthermore, molecular docking analysis was performed to explore potential interactions between MBE bioactive components and LuxS , a key quorum‐sensing enzyme implicated in probiotic viability.

RESULTS:

Administration of MBE notably reduced weight loss induced by CTX , reinstated indices of the spleen and thymus, enhanced the proliferation of both T and B lymphocytes, stimulated cytokine expression, upregulated the CD4+ / CD8+ T cell ratio, and improved splenic histopathological architecture. MBE successfully reduced damage to the intestinal mucosa by enhancing the expression of essential tight junction proteins, thereby reinforcing intestinal barrier integrity. MBE also elevated the intestinal levels of cytokines, probably through activation of the MAPK signaling pathway. Furthermore, gut microbiota analysis demonstrated that MBE restored the ratio of Firmicutes/Bacteroidetes, reduced the abundance of pathogenic bacterial taxa and significantly enriched Lactobacillus reuteri , a beneficial probiotic species. Molecular docking analysis identified trigonelline and procyanidin B2 , two bioactive components of MBE , as potent inhibitors of LuxS . This inhibition likely contributed to the enhanced viability of L. reuteri .

CONCLUSION:

Our findings highlight the multifaceted protective benefits of MBE in counteracting CTX ‐induced immune suppression and intestinal damage. We found that MBE exerts prebiotic effects by restoring gut microbiota balance and enhancing probiotic activity likely via quorum sensing modulation. These findings highlight its potential as a dietary supplement to synergize with probiotics for gut–immune health during chemotherapy. © 2025 Society of Chemical Industry.

News (Medical) associated with Lactobacillus reuteri

06 Feb 2026

·ibtherapeutics.com

Infant Bacterial Therapeutics AB (publ) Year-end-report January 1 – December 31, 2025

Message from CEO IBT's plan to apply for marketing approval in the US through a so-called accelerated application remains unchanged. The development program for IBP-9414 is “Breakthrough Designated,” which gives us the opportunity to submit the marketing authorization application in several parts, rather than all at once. IBT has made use of this opportunity, and so the FDA reviewed the clinical documentation already in the summer of 2025. During the fall, we held meetings with the FDA where IBT answered clinical questions about the results of our Phase III study, “The Connection Study.” We are therefore very pleased that the FDA is encouraging IBT to work towards market approval. What remains can be summarized in two parts: The first is to ensure continued documentation of the clinical effects of IBP-9414, with a focus on its ability to reduce mortality in premature babies. At a meeting on 19th December 2025, IBT and the FDA agreed that IBT would develop a proposal for a study intended to be conducted after the launch of IBP-9414. The study proposal is being developed with clinical and statistical experts. The study design is based on the following four principles: Feasibility – To ensure that the study is feasible. Equipoise – To ensure that healthcare professionals do not withhold a treatment that is believed to help the patient. Ethics: To ensure that good morals are upheld. Meeting “CBER Standards”: To ensure that legal requirements are met in the manner deemed appropriate by the FDA The second part we are working on is the validation of production at the companies that will manufacture the commercial volumes of IBP-9414. The plan is for our German manufacturer of the drug substance to be ready in April 2026. The product will then be further processed into a drug by filling vials and freeze-drying them at our manufacturer in the Netherlands. Despite a somewhat tight schedule, I consider our timetable to be realistic, based on the cooperation with suppliers and working methods we have today. Shortly after the drug is manufactured, IBT intends to submit an application for marketing approval in the US. Most of the documents required for the application have been completed, and the remainder are expected to be ready once we have completed the two steps above. Discussions are continuing with several partners regarding sales partnerships and distribution of IBP-9414. For the US market, IBT intends to register IBP-9414 with the FDA itself and handle distribution and sales. At the same time, we are working with potential partners in other parts of the world, with the request that the partner convert the US/EU-adapted registration to local requirements. In January 2026, IBT received the welcome news that the clinical results from “The Connection Study” will be published in the scientific journal Pediatric Research shortly. This is the first publication of study results from “The Connection Study,” which showed that IBP-9414 is safe and reduces mortality by 27% in premature infants. IBP-9414 has Rare Pediatric Disease Designation, which means that IBT can be awarded a Priority Review Voucher (“PRV”) upon market approval. The program, that previously had an end date of 30th September 2026, has now been extended to 30th September 2029. The last known sale value for a PRV was 200MUSD. At the end of Q4 2025, IBT had cash reserves of SEK 144 million. The company has very low fixed costs and is therefore a sustainable company. Stockholm February 5, 2026 Staffan Strömberg, CEO *Operating profit includes exchange rate effects on currency investments intended to secure future payments. During the fourth quarter, these amounted to KSEK -1,162 (5,552) and during the reporting period to KSEK -7,043 (5,445). Significant events during the fourth quarter (October – December) On November 20, 2025, IBT announced that it had entered into a partnership with Recipharm Advanced Bio for the production of drug substance. On November 25, 2025, IBT announced that it had decided to proceed with an accelerated approval process for IBP-9414. On December 11, 2025, IBT announced that it had entered into a partnership with BioConnection for the production of drugs. Significant events during the reporting period (January – December) On March 28, 2025, IBT announced that the FDA had granted IBP-9414 “Breakthrough Therapy Designation” for its potential to reduce gastrointestinal-related mortality. On May 8, IBT announced that the Clinical Study Report (CSR) for “The Connections Study” had been submitted to the FDA. The report contains data from the Phase 3 clinical trial that was completed in 2024. Summary of selected financial data

Phase 3Breakthrough TherapyFast TrackAccelerated Approval

02 Dec 2025

·www.pharmamanufacturing.com

Recipharm partners with Infant Bacterial Therapeutics on drugs for premature infants

Recipharm Advanced Bio, part of global contract development and manufacturing organization Recipharm, and pharma company Infant Bacterial Therapeutics AB (IBT) announced the initiation of Process Performance Qualification (PPQ) for IBT’s lead product, IBP-9414, which targets mortality and gastrointestinal injury in premature infants. The PPQ program will be conducted at Recipharm’s microbial manufacturing facility in Cuxhaven, Germany, which offers integrated bacterial capabilities covering the full product lifecycle from pre-clinical development through commercial supply, according to Recipharm. The Cuxhaven site provides comprehensive support including viral and bacterial cell bank production, development, scale-up, as well as production of virus-based therapies and vaccines (AAV, lentivirus, oncolytic virus), sterile fill-finish, analytical services, recombinant proteins, and monoclonal antibodies. “Partnering with Infant Bacterial Therapeutics on this breakthrough therapy underscores our shared commitment to addressing critical unmet needs in vulnerable patient populations,” Vikas Gupta, president of Recipharm Advanced Bio, said in a statement. “By combining IBT’s innovative approach with Recipharm Advanced Bio’s microbial expertise and accelerated path to manufacturing, we are ensuring PPQ and commercial readiness are delivered on a fast and reliable timeline, bringing this lifesaving treatment for premature infants fast to market.” In October, Recipharm announced that its Cuxhaven facility has been designated as the company’s Center of Excellence for Analytical Services tailored to advanced modalities. With more than 15 years of experience in analytical method development and qualification, Cuxhaven’s team specializes in both compendial and non-standard assays, including microbiological and viral assay validation, nucleic acid quantification, and advanced molecular techniques such as ddPCR, qPCR, and Western blot. According to Recipharm, these capabilities make the site a key asset for biologics and advanced therapy medicinal products (ATMPs). The facility in Cuxhaven provides support in viral and bacterial cell bank production, development, scale-up, and production of virus-based therapies and vaccines (AAV, lentivirus, oncolytic virus), sterile fill and finish, analytical services, recombinant proteins and monoclonal antibodies (mAbs). "IBP-9414 will be the first LBP (Live Biotherapeutic Product) globally, and after careful consideration, we now proceed to Process validation for Drug substance with Recipharm Advanced Bio in Cuxhaven,” says Staffan Strömberg, CEO at IBT. “With the possibility of Recipharm Advanced Bio being a future drug substance supplier, we are strengthening our commercial supply chain possibilities. We feel that we are in good hands for this work, given Recipharm Advanced Bio's deep expertise and understanding of pharmaceutical quality requirements for scalable commercial manufacturing." Recipharm Advanced Bio has the ability to enable comprehensive and accelerated manufacturing via its network of advanced therapy medicinal products facilities, along with its centers of excellence, in order to support partners from early development through commercial supply. In October, Recipharm announced the inauguration of newly commissioned parenteral development and sterility laboratories at its Bengaluru, India site, according to the company. The purpose-built facilities are designed to enhance Recipharm’s sterile pharmaceutical development and testing capabilities, expand its analytical services function and build on its established strengths in oral dosage and advanced therapies.

Microbial therapy

14 Nov 2024

·ibtherapeutics.com

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024

Message from the CEO This quarter, IBT completed the global Phase 3 clinical trial “The Connection Study” for the drug candidate IBP-9414. On July 8, we reported that the last patient was treated. On August 30, we reported topline data to the market. Since then, we have continued to analyze the data with our experts. Our conclusion is that our drug candidate IBP-9414 meets the requirements for a pharmaceutical product, meaning we have now documented both the potency and safety of IBP-9414. We see that IBP-9414's safety profile is generally very good, in line with, or in some areas even better, than placebo. When we look at the causes of death in infants, we see a clear reduction in the number of deaths in the cardiopulmonary and gastrointestinal areas after IBP-9414 administration when compared to the children receiving placebo. See figure 1. Figure 1: Reported causes of death grouped by organ class in “The Connection Study” If we look at survival as a function of time, we see an clear effect of IBP-9414 after two weeks of treatment. See figure 2 (in attachment) on the Y-axis we see survival and on the X-axis we see the number of days after the first dose is administered. The overall reduction in mortality of 27% in the IBP-9414 treatment group compared to the placebo group for all preterm infants in the phase 3 study is clinically relevant. In addition, when examining deaths occurring after 14 days of treatment, the relative risk of death is further reduced to 46%. These are fantastic results and as there is no treatment alternative on the market, we at IBT are highly motivated to continue our work to register our product. After further analysis of the study data, scientifically accepted reasons have emerged as to why it has been difficult to measure our primary endpoints in the study. There are different pathways for how a product can be registered as a medicine. We will therefore have a meeting with the FDA, which is scheduled for December 2024. Then we will update timetables for the remaining parts of IBP-9414's development work. In parallel with our communication with the authorities, we are ensuring that we can produce large volumes of IBP-9414 to a high standard of quality. We are expanding our supplier network for manufacturing and product analysis. The first commercial batches are planned to be produced in 2025. Another ongoing activity is the publication of the full results from “The Connection study”, IBT's data from the study will be presented at Hot Topics in Neonatology, December 9, by Professor Josef Neu who is also the principal investigator of the study. IBT also aims to publish the results in several scientific publications as soon as possible. On October 25th, IBT was the only company invited to participate in a one-day meeting organized by the US authorities in Washington DC. The purpose of the meeting was to bring together academia, government and industry to discuss the Live Biotheapeutic Products class of drugs and how such products can be developed to prevent NEC. Clinical results for IBP-9414 were also presented during the meeting. In conclusion, I would like to thank all the staff in the 95 hospitals around the world who collected data for the infants. I would also like to extend a very big thank you to the IBT staff who executed the largest randomized study ever conducted on preterm infants in a very professional manner. We now look to the future with confidence, as IBT has no doubt that the results of our phase 3 study demonstrate that premature babies do better with IBP-9414 than without it. Stockholm November 13, 2024 Staffan Strömberg, CEO Financial overview for the period * Operational income includes exchange rate effects on foreign currency deposits to secure future outflows during the third quarter amounting to KSEK -4 280 (-448) and during the reporting period amounting to SEK -108 (7 313) Significant events during the third quarter (Jul-Sep) On July 8, 2024, IBT announced that the last patient in the global Phase 3 clinical program “The Connection Study” has been treated. This means that the clinical development program is completed. On August 15, 2024, IBT announced they had received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the drug candidate IBP-9414. On August 30, 2024, IBT announced phase III study didn´t showed significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality. Significant events during the reporting period (Jan-Sep) On April 4, 2024, IBT announced that the last patient out of a total of 2,158 premature infants had been enrolled in the global Phase 3 clinical program (“The Connection Study”) for the development of IBP-9414. Results from “The Connection Study” were expected Q3 2024. Selected financial data Contacts Staffan Strömberg, CEO Maria Ekdahl, CFO info@ibtherapeutics.com +46 76 219 37 38 About Us Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are since September 10, 2018, listed on Nasdaq Stockholm (IBTB). IBT is a pharmaceutical company whose purpose is to develop and commercialize drugs for diseases affecting premature babies. During the 12 years of drug development IBT has gained unique expertise in the field of drugs using live bacteria as active substances. This is a key competitive factor for our development programs. IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in human breast milk. IBP-9414, is expected to be the first product in the new class of biologics called "Live Biotherapeutic Products" for premature infants. The drug development of IBP-9414 is currently in its final stages for this important product for premature babies. The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP-1016, for the treatment of gastroschisis, a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. IBP-1118 to prevent retinopathy of prematurity (ROP), one of the leading causes of blindness in premature babies, and IBP-1122 to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital infections. Through the development of these drugs, IBT can address medical needs where no sufficient treatments are available.

Phase 3Clinical Result

100 Deals associated with Lactobacillus reuteri

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lactobacillus reuteri	A07FA01	DB14224

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gastrointestinal Diseases	India	BioGaia AB	30 Apr 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enterocolitis, Necrotizing	Phase 3	Spain	Infant Bacterial Therapeutics AB	14 Jun 2019
Dysentery	Phase 3	Botswana	BioGaia AB	01 Jun 2016
Constipation	Phase 2	Japan	BioGaia AB	30 Dec 2016
Obstetric Labor, Premature	Phase 2	Sweden	Infant Bacterial Therapeutics AB	28 Dec 2015
Diabetes Mellitus, Type 2	Phase 2	Sweden	BioGaia AB	26 Apr 2012
Colic	Clinical	China	BioGaia AB	01 Mar 2016
Pregnancy	Clinical	Sweden	BioGaia AB	01 Nov 2015
Gastroschisis	Preclinical	United States	Infant Bacterial Therapeutics AB	30 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02765217 (PEARL Study, Pubmed \| Eur J Pediatr)	Phase 4	Diarrhea	-	Limosilactobacillus reuteri DSM 17938 + amoxicillin-clavulanate	xkplcdwoyd(ekqxtloneu) = egpcgjdouo ownovqsses (vnslpqvvek, 0.30 - 0.7) View more	Positive	09 Jun 2025
				Placebo + amoxicillin-clavulanate	xkplcdwoyd(ekqxtloneu) = zrbldhnvab ownovqsses (vnslpqvvek, 0.30 - 0.7) View more
NCT03978000 (Company_Website) Manual	Phase 3	Enterocolitis, Necrotizing	2,117	IBP-9414	hvmtozdjqb(zaljxorqkt) = tscjyidbgd fmqcjwfqlk (cfgrpkdwmt ) View more	Positive	14 Nov 2024
				Placebo	hvmtozdjqb(zaljxorqkt) = vnttkowbym fmqcjwfqlk (cfgrpkdwmt ) View more
NCT03978000 (Company_Website) Manual	Phase 3	Enterocolitis, Necrotizing	2,153	IBP-9414	lupqbezaql(ryowabrsvi) = ragiuteizj kziqxzayrg (itnewbyxew ) View more	Negative	30 Aug 2024
				Placebo	lupqbezaql(ryowabrsvi) = pjxerkmdaj kziqxzayrg (itnewbyxew ) View more
NCT05701683 (Pubmed \| Helicobacter)	Phase 4	Helicobacter pylori infection	195	non-viable Lactobacillus reuteri (Placebo)	bugkiuknfm(uambckemho) = zaujtlhgun ykibrxtwqw (pibmygvbhi ) View more	Negative	10 Oct 2021
NCT02723344 (Pubmed \| Front Neurol)	Phase 1	Stress Disorders, Post-Traumatic C-reactive protein	75	Immunomodulatory Probiotic Intervention	adwsvacjls(iehaglyuoj): P-Value = 0.006	-	20 Oct 2020
				Immunomodulatory Probiotic Intervention
NCT01541046 (Pubmed \| J Pediatr)	Phase 2	Colic	52	Lactobacillus reuteri DSM 17938	yphindeffe(tyfuywtzyz) = bcbyiixvcs sbazhopgwj (nmdcqfuuap )	Positive	01 Jan 2015
				Placebo	yphindeffe(tyfuywtzyz) = sgreimcuzp sbazhopgwj (nmdcqfuuap )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lactobacillus reuteri

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation